Oruka Therapeutics (ORKA) is back in focus after reporting Phase 2a data showing high complete skin clearance rates for psoriasis patients on ORKA-001, followed almost immediately by a US$700.35 million follow on stock offering.

At a latest share price of US$62.58, Oruka’s 1 day share price return of 8.52% and 7 day return of 9.34% follow a rapid 90 day gain of 82.45% and year to date share price return of 121.37%. The 1 year total shareholder return is very large at 4.8x, suggesting strong momentum around the recent Phase 2a data and sizable equity raise.

If this kind of move has your attention, it could be a good moment to see what else is happening across healthcare and immunology, starting with 33 healthcare AI stocks

With the stock up sharply and analysts’ average price target sitting far above the current US$62.58 level, the key question now is simple: is this a genuine opportunity or is the market already pricing in future growth?

Preferred Price to Book of 8x: Is It Justified?

On a P/B of 8x at the last close of $62.58, Oruka trades well above both the US Biotechs industry and its closest peers. Anyone chasing the recent momentum is paying a premium for each dollar of net assets.

P/B compares the company’s market value to its book value. This is especially relevant for a clinical stage biotech that currently reports no revenue and a net loss of $84.31m. With Oruka forecast to remain unprofitable and to have no revenue next year, this premium P/B level reflects expectations about its pipeline and future outcomes rather than current earnings power.

Compared with the US Biotechs industry average P/B of 2.3x and a peer average of 5.4x, Oruka’s 8x multiple stands out as materially higher. This means the market is assigning a richer valuation than both the broader group and closer comparables on this metric.

Result: Price-to-book of 8x (OVERVALUED)

However, there is still real risk that future trial readouts or setbacks in ORKA-002 and the broader pipeline could quickly challenge today’s premium valuation.

Next Steps

The sentiment so far may feel cautiously optimistic, so if the story interests you, take a closer look at the details and move quickly to shape your own view by reviewing the 5 important warning signs

Looking for more investment ideas?

If Oruka has sharpened your focus, do not stop there. Broaden your watchlist with a few targeted ideas that could fit different goals and risk levels.

• Target potential mispricing by scanning 50 high quality undervalued stocks that combine quality fundamentals with prices that may not fully reflect their underlying strength.
• Strengthen your income stream by reviewing 13 dividend fortresses offering higher yields that might suit investors who value regular cash returns.
• Prioritize resilience by checking 69 resilient stocks with low risk scores built around businesses that score well on financial stability and risk controls.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.